Quantcast
Last updated on April 21, 2014 at 7:52 EDT

Latest Szilard Voros Stories

2013-10-21 08:29:25

- Corus® CAD is Effective in Excluding the Diagnosis of Obstructive Coronary Artery Disease in the Primary Care Setting and Helps Reduce Unnecessary Healthcare Expense - PALO ALTO, Calif., Oct. 21, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced results of a multi-center, real-world registry study demonstrating the clinical utility of Corus® CAD, a blood-based gene expression test, in the evaluation of...

2013-10-13 08:21:22

Chief Clinical Strategy Officer will focus on HDL, Inc.'s recent ROI study showing lowered costs, improved outcomes with company patients BETHESDA, Md., Oct. 13, 2013 /PRNewswire/ -- Dr. Szilard Voros, Chief Clinical Strategy Officer of Health Diagnostic Laboratory, Inc., will present the results of a recently released study showing reduced healthcare costs and improved outcomes in patients who use HDL, Inc.'s advanced testing and health management at the Patient-Centered Primary...

2013-09-03 08:28:48

Corus CAD Gene Expression Test Helped Cardiologists Determine Which Patients with Symptoms Suggestive of Obstructive Coronary Artery Disease (CAD) Did Not Require Further Cardiac Testing PALO ALTO, Calif., Sept. 3, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the presentation of results from the Investigation of a Molecular Personalized Coronary Gene Expression Test on Cardiology Practice Pattern...

2013-08-26 16:23:34

- Sex-Specific Blood-based Genomic Test Helps Exclude the Diagnosis of Obstructive CAD in Symptomatic Patients - PALO ALTO, Calif., Aug. 26, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the publication of a comprehensive review of the evidence demonstrating that Corus(®) CAD, a blood-based gene expression test, can help clinicians accurately and safely exclude obstructive coronary artery disease (CAD)...

2013-07-18 08:29:50

- Two Studies to be Presented at "What a Difference an X Makes: The State of Women's Health Research" Validate the Accuracy and Clinical Utility of Corus® CAD, the Only Sex-Specific Test for the Assessment of Obstructive Coronary Artery Disease - PALO ALTO, Calif., July 18, 2013 /PRNewswire/ -- CardioDx, Inc., a leader in the field of cardiovascular genomic diagnostics, today announced that the company will present two studies demonstrating the accuracy and clinical utility of...

2013-05-30 08:29:57

PALO ALTO, Calif., May 30, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that the company will present at the Jefferies 2013 Global Healthcare Conference, taking place June 3-6, 2013 in New York, NY. David Levison, the company's President and Chief Executive Officer, will provide an overview of CardioDx and Corus(®) CAD, the only clinically validated gene expression test for obstructive coronary artery disease (CAD) on...

2013-05-20 08:27:53

- Use of Corus® CAD Led to a Statistically Significant Reduction in Additional Cardiac Testing - PALO ALTO, Calif., May 20, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced the publication of the IMPACT-CARD (Investigation of a Molecular Personalized Coronary Gene Expression Test on Cardiology Practice Pattern) trial in Critical Pathways in Cardiology. This prospective study conducted at Vanderbilt University...

2013-05-17 12:23:32

- Study Presented at the Quality of Care and Outcomes Research 2013 Scientific Session - PALO ALTO, Calif., May 17, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced results of a clinical utility study of the Corus® CAD gene expression test in the real-world primary care setting for evaluating patients with signs and symptoms suggestive of obstructive coronary artery disease (CAD). The multicenter, prospective...

2013-04-25 08:35:04

- Corus CAD is the Only Clinically Validated Gene Expression Test for the Assessment of Obstructive Coronary Artery Disease - PALO ALTO, Calif., April 25, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced it has entered into an agreement granting to Core Diagnostics India the exclusive right to market and sell CardioDx's Corus(®) CAD diagnostic test in India. Corus CAD is a noninvasive blood-based gene expression...

2013-03-04 08:29:07

PALO ALTO, Calif., March 4, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, announced that clinical data from studies of Corus® CAD, the only clinically validated gene expression test for obstructive coronary artery disease (CAD), will be presented at the American College of Cardiology 62(nd) Annual Scientific Session taking place March 9-11, 2013 at the Moscone Center in San Francisco, CA. (Logo:...